Cytotoxic bispecific monoclonal antibody, its production and use

Details Cytotoxic bispecific monoclonal antibody, its production and use Cytotoxic bispecific monoclonal antibody, its production and use

1992-02-27

1993-06-08

Nucker, Christine M.

Drug, bio-affecting and body treating compositions

Lymphokine

5303873, A61K 3900, A61K 3514, C07K 300, C07K 1300

Patent

active

052177130

ABSTRACT:
The present invention discloses, a bispecific monoclonal antibody to an ansamitocin derivative and a target antigen, particularly tumor-associated antigen, which can carry an ansamitocin derivative in a stable and inactive form at other sites than the target and release the active-form ansamitocin derivative at the target site, so that an anticancer agent having excellent durability and selectivity with little adverse action can be prepared using the bispecific monoclonal antibody and ansamitocin derivatives.

REFERENCES:
Pirker et al. (1985) Cancer Research 45:751-757.
Iwasa, et al., The Physio-Chemical Biology (1988), vol. 32, No. 8, p. 225.
Higashide, et al., Nature, 270:721-722 (1977).
Klausner, Bio/Technology, 5:867-868 (1987).

Affiliated with

Also associated with

Rating

Cytotoxic bispecific monoclonal antibody, its production and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytotoxic bispecific monoclonal antibody, its production and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic bispecific monoclonal antibody, its production and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1932243